Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
237 hedge funds and large institutions have $3.19B invested in Blueprint Medicines in 2022 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 80 increasing their positions, 87 reducing their positions, and 39 closing their positions.
151% more call options, than puts
Call options by funds: $27.2M | Put options by funds: $10.8M
4.96% more ownership
Funds ownership: 101.06% → 106.02% (+5%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
8% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 87
5% less funds holding
Funds holding: 249 → 237 (-12)
15% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 39
17% less capital invested
Capital invested by funds: $3.82B → $3.19B (-$631M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$190M |
| 2 |
Morgan Stanley
New York
|
+$84.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40.9M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$40.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$26.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$82.6M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$26.4M |
| 3 |
CC
Casdin Capital
New York
|
-$23.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$21.4M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$18.6M |
BPMC Hedge Fund Activity: Q2 2022 in Review
237 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2022, worth a combined $3.19B — down 17% from $3.82B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of BPMC and 33 opened new positions — a net loss of 6 holders — while 87 trimmed existing stakes and 80 added.
The largest buyer was Fidelity Investments, adding an estimated $190M. The largest seller was Wellington Management Group, cutting an estimated $82.6M.
- 237 institutional investors held Blueprint Medicines (BPMC) as of Q2 2022, down from 249 in Q1 2022.
- Funds reported $3.19B of Blueprint Medicines stock for Q2 2022, down 17% quarter-over-quarter.
- 33 funds opened new Blueprint Medicines positions in Q2 2022 and 39 closed out, a net change of -6 holders.
- The largest Blueprint Medicines buyer in Q2 2022 was Fidelity Investments, an estimated $190M added.
- The largest Blueprint Medicines seller in Q2 2022 was Wellington Management Group, an estimated $82.6M sold.
Based on aggregated 13F filings for Q2 2022.